Small-Cap Stocks: SCS and HAYW Face Challenges
Steelcase (SCS), Hayward (HAYW), and Amneal (AMRX) – Three Stocks to Avoid
For investors seeking outsized returns, the small-cap market presents a compelling, albeit complex, opportunity. These smaller companies, often overlooked by larger investment firms and traditional analysts, can deliver significant gains. However, this segment of the market is inherently risky, characterized by a lack of readily available price targets and a heightened potential for volatility. StockStory’s mission is to guide investors through this landscape, identifying winning stocks while mitigating potential losses. Based on our rigorous analysis, we’ve identified three small-cap stocks – Steelcase, Hayward, and Amneal – that currently don’t meet our investment criteria. Understanding why these companies are currently under our radar is crucial for any investor considering their inclusion in a portfolio.
Steelcase (SCS): A Declining Market Leader
Steelcase, established in 1912 as a pioneer in metal office furniture, is a global manufacturer of workplace solutions, encompassing desks, chairs, architectural products, and associated services. The company’s core business, like many in the office furniture sector, is currently facing substantial headwinds. Over the past five years, sales have experienced a consistent decline, dropping by 3.2% annually. This downward trend reflects broader shifts in the market – the rise of remote work, a decrease in overall office occupancy rates, and increased competition from manufacturers offering more flexible and adaptable solutions. Furthermore, the company’s earnings per share have been steadily decreasing, a common indicator of sustained challenges. A Return on Invested Capital (ROIC) of 6.4% suggests that management has struggled to identify and capitalize on attractive investment opportunities, adding further concern. As of today’s trading, Steelcase is valued at $9.87 per share, with a price-to-earnings (P/E) ratio of 9.1x based on forward earnings estimates. Our analysis indicates that the current valuation doesn’t justify the persistent decline in its core business, leading us to advise caution.
Hayward (HAYW): Stagnant Growth and Declining Returns
Hayward, credited with inventing the first variable-speed pool pump in 1953, is a manufacturer of residential and commercial pool equipment and accessories. Despite its established position in the industry, Hayward has recently shown signs of underperformance. Organic revenue growth has fallen short of our benchmarks over the last two years, a critical indicator for assessing future potential. This suggests that the company may need to innovate its product offerings, strategically adjust its pricing, or refine its go-to-market strategy. Adding to these concerns, Hayward experienced a significant issuance of new shares over the past five years, which contributed to a 58.1% annual decline in earnings per share. Simultaneously, revenue growth has occurred, illustrating an inefficient use of capital. The company’s returns on capital are already weak, and ongoing investments are not producing the desired results. The current stock price of $13.82 places a valuation ratio of 18.2x on forward P/E estimates, implying that the company’s growth prospects are not adequately reflected in its market value. We believe a more thorough examination of the company’s operational challenges is necessary before considering an investment.
Amneal (AMRX): Eroding Profitability and Capital Intensity
Amneal Pharmaceuticals, founded in 2002 and now a major producer of generic drugs, has experienced a recent decline in its financial performance. The company develops, manufactures, and distributes generic medicines, specialty branded drugs, biosimilars, and injectable products, primarily serving the U.S. healthcare market. Over the last five years, the company’s free cash flow margin has dropped by an alarming 12.1 percentage points, indicating an increasing reliance on capital expenditures. This trend suggests that competition within the pharmaceutical sector is intensifying, forcing Amneal to become more capital-intensive. Furthermore, management has struggled to find compelling investment opportunities, as indicated by below-average returns on capital. Given the capital-intensive nature of the pharmaceutical industry, a strong return on capital is crucial for sustainable growth. The current stock price of $7.05 per share reflects a valuation ratio of 10.3x on forward P/E estimates and highlights the challenges the company is facing. While Amneal’s growth potential in the generic drug market remains, our analysis suggests that the current valuation doesn’t fully account for the intensifying competitive pressures and declining profitability.
Looking Ahead: Stocks Delivering Long-Term Gains
Despite the caution surrounding Steelcase, Hayward, and Amneal, some companies demonstrate a strong capacity for long-term growth, regardless of broader economic or political conditions. A compelling example is Nvidia, which saw an incredible 2,183% return between December 2019 and December 2024, while other companies like Axon delivered a robust 711% five-year return. These returns, achieved during a period of significant market volatility and political uncertainty, demonstrate the potential of under-the-radar businesses to generate substantial returns. StockStory continues to identify and curate “High Quality” stocks – those that consistently outperform the market, delivering market-beating returns. We encourage investors seeking significant gains to explore these options and discover their own winning stocks.
